Hope for Hard-to-Treat lung infection: old drug shows promise

NCT ID NCT02968212

Ongoing Disease control Sponsor: Oregon Health and Science University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called clofazimine for people with a chronic lung infection caused by Mycobacterium avium complex (MAC). The goal is to see if adding clofazimine to standard treatment helps clear the bacteria from sputum and improves walking ability and fatigue. About 102 adults with confirmed MAC lung disease are taking part. The drug is not a cure, but aims to better control the infection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYCOBACTERIUM AVIUM COMPLEX are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Mycobacterium avium complex disease pulmonary non-tuberculous mycobacterial infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYCOBACTERIUM AVIUM COMPLEX

Contacts and locations

Show contact details

Locations

Louisiana State University

Baton Rouge, Louisiana, 70803, United States
National Jewish Health

Denver, Colorado, 80206, United States
Oregon Health & Science University

Portland, Oregon, 97239, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of South Florida

Tampa, Florida, 33620, United States
University of Texas Health Science Center

Tyler, Texas, 75708, United States